Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Accounts Payables (2024 - 2025)

BioAge Labs (BIOA) has disclosed Accounts Payables for 2 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 33.97% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2025, up 33.97% year-over-year, with the annual reading at $2.7 million for FY2025, 33.97% up from the prior year.
  • Accounts Payables hit $2.7 million in Q4 2025 for BioAge Labs, down from $5.0 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $5.0 million in Q3 2025 to a low of $1.3 million in Q2 2025.